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Dear Editor
The CVD 103-HgR vaccine (Vaxchora), described in “Re-born in the USA: Another cholera 
vaccine for travellers” by Dr. Freedman, will soon be available to adult travelers to cholera-
affected areas [1]. In the United States, most cholera cases reported to the national Cholera 
and Other Vibrio Illness Surveillance (COVIS) system are associated with travel to cholera-
affected areas. In 2011, after the cholera epidemic began in Haiti, 42 cases of laboratory-
confirmed cholera were reported [2]. Few cases were reported in 2012 (18), 2013 (14), and 
2014 (7). Although cholera is rare in the United States, cases reported to COVIS 
underestimate the risk to travelers for several reasons. First, cholera is under-reported in the 
United States, as testing stool specimens for Vibrio cholerae is not routine. Second, although 
cholera can be life-threatening, illness is usually fairly mild and self-limited, so ill persons 
may not seek medical care. Third, the incubation period is short, thus many infections likely 
occur during travel rather than after return to the United States. Such illnesses are not 
captured by COVIS. Among 90 cases of travel-associated cholera in the United States 
reported from 2001 to 2011, reasons for travel included visiting friends and relatives (62%), 
medical missions or other relief work (9%), tourism (7%), and business (7%) [3].
In June 2016, the Advisory Committee on Immunization Practices (ACIP) approved a 
recommendation for CVD 103- HgR vaccine for adult (18–64 years old) travelers to areas of 
active cholera transmission [4]. The ACIP considered additional risk factors for travelers to 
*Corresponding author. 1600 Clifton Road NE, Mailstop C-09, Atlanta, GA 30329, USA, kwong@cdc.gov (K.K. Wong). 
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
Conflict of interest
No conflicts of interest to disclose.
HHS Public Access
Author manuscript
Travel Med Infect Dis. Author manuscript; available in PMC 2018 January 22.
Published in final edited form as:
Travel Med Infect Dis. 2016 ; 14(6): 632–633. doi:10.1016/j.tmaid.2016.09.011.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
these areas, including increased risk of toxigenic V. cholerae O1 exposure and increased risk 
of severe outcomes. However, only travel to an area of active cholera transmission was 
included in the approved recommendation; other risk factors are not mentioned in the 
recommendation. The proposed definition of an area of active cholera transmission is a 
province, state, or other administrative subdivision within a country with endemic or 
epidemic cholera caused by toxigenic V. cholerae O1. It includes areas with cholera activity 
within the last 1 year that are prone to recurrence of cholera epidemics; it does not include 
areas where rare sporadic cases have been reported. The vaccine is not routinely 
recommended for most travelers from the United States, as most travelers from the United 
States do not visit areas with active cholera transmission. CDC is developing resources for 
clinicians and travelers to learn which travel destinations may have active cholera 
transmission.
No information is available about the duration of protection provided by Vaxchora beyond 
3–6 months, so the ACIP recommendation does not address reimmunization.
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